Johnson & Johnson (JNJ)
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Johnson & Johnson is doing 'great things for patients,' CFO says
Johnson & Johnson executive vice president and CFO Joseph Wolk discusses the company's performance and President Donald Trump's healthcare agenda on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #theclamancountdown #johnsonandjohnson #jnj #healthcare #health #patients #innovation #pharma #medicine #trump #donaldtrump #business #economy #ceo #agenda
Johnson & Johnson Says Product Launches, Regulatory Approvals Drive Growth
Johnson & Johnson's MedTech segment saw its worldwide operational sales grow 5.4% year over year in 2025, reaching about $33.8 billion, the company said in a Wednesday (Jan. 21) earnings release. The segment slightly outpaced the healthcare solution provider's other segment, Innovative Medicine, whose worldwide operational sales were up 5.
Johnson & Johnson (JNJ) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Tops Q4 Earnings and Revenue Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.46 per share, beating the Zacks Consensus Estimate of $2.43 per share. This compares to earnings of $2.04 per share a year ago.
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
AtaiBeckley seen as key beneficiary of Spravato's strong growth: Jefferies
Jefferies analysts said the continued commercial momentum of Johnson & Johnson (NYSE:JNJ)'s Spravato (esketamine nasal spray) could provide a meaningful tailwind for the broader psychedelics sector, with AtaiBeckley NV (NASDAQ:ATAI, XETRA:9VC) a direct beneficiary. As reported by J&J on Wednesday, Spravato's fourth quarter 2025 sales in treatment-resistant depression (TRD) rose 10% sequentially to $503 million worldwide.
J&J Stock Down Despite Q4 Earnings Beat, Oncology Drugs Drive Sales
JNJ beat Q4 earnings and sales estimates as strong oncology drug growth, led by Darzalex, offset biosimilar pressure on Stelara.
Johnson & Johnson reports Q4 earnings beat, issues 2026 guidance above forecasts
Johnson & Johnson (NYSE:JNJ) reported fourth quarter and full-year 2025 results that came in above market expectations and issued 2026 guidance that was modestly ahead forecasts. For Q4, Johnson & Johnson reported sales of $24.6 billion, representing reported growth of 9.1% year-over-year and operational growth of 7.1%.
5 Things to Know Before the Stock Market Opens
Stock futures are slightly lower this morning after sinking on Tuesday owing to new tariff threats from President Donald Trump; investors are awaiting Trump's speech today at the World Economic Forum in Davos, amid ongoing tensions related to the president's efforts to acquire Greenland; Netflix stock is tumbling after the streaming giant released earnings and said it would pause stock buybacks to help finance the Warner Bros. Discovery acquisition; Johnson & Johnson shares are moving lower after the company's fourth-quarter profits fell short of Wall Street estimates; and United Airlines shares are rising after its results topped expectations.
J&J expects to hit $100 billion in revenue next year after new strategy pays off
Johnson & Johnson sees revenue grow 9% in the fourth quarter, amid strength in its cancer drugs.
Johnson & Johnson forecasts 2026 profit above Wall Street estimates
Johnson & Johnson on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of "hundreds of millions of dollars" from the drug pricing deal it signed with the Trump administration earlier this month.
